OpiAID Strength Band Platform for Opioid Use Disorder
Official title: Development of the OpiAID strength band platform
Funded at Opiaid, INC. · NIH-11300218 · Data updated 2026-11-12
A new AI-powered wearable monitoring platform aims to help people starting medication-assisted treatment for opioid use disorder by guiding dosing and tracking withdrawal symptoms and well-being.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Opiaid, INC. NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project start | May 1, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,132,593 |
| NIH project number | 5R44DA058474-03 |
| Project ID | NIH-11300218 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with opioid use disorder starting or currently undergoing induction with MOUD who are receiving care in clinical settings.
✕Less likely to help
Individuals not using MOUD or not on induction protocols may not benefit from this platform.
What this research studies
This project develops the OpiAID Strength Band Platform, a digital tool that uses AI to monitor patients on opioid use disorder treatment and support safer induction dosing. It leverages accelerometer data and behavioral metrics to track withdrawal symptoms and activity, informing clinicians about when to adjust initial agonist doses. The goal is to reduce withdrawal distress, improve treatment retention, and lower the risk of relapse during the MOUD induction phase. The approach focuses on real-time data collection, patient-friendly feedback, and clinician sensing to personalize care.
Why it matters
Potential benefit: If successful, patients could experience smoother MOUD induction, fewer withdrawal-related relapses, and better engagement with treatment.
How similar studies have gone: Previous MOUD induction strategies show that personalized dosing and monitoring can improve retention, suggesting potential for similar benefits with AI-supported monitoring.
Where this research is happening
-
Opiaid, INC.
Wilmington, United States Active
Researchers
- Principal investigator: Brookins, Trace — Opiaid, INC.
- Study coordinator: Brookins, Trace
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.